- In Q42021 (likely at SITC), AGEN is anticipated to publish updated 1181/Bal Phase 2 clinical data in MSS-CRC that shows 1181/Bal significantly outperforms current FDA approved 3rd line standard-of-care.
- The broader clinical/investment community may see much faster patient enrollment than planned leading to an FY2022 BLA submission, accelerated approval in 1H2023 & Blockbuster sales potential just in MSS-CRC.
- If 1181/Bal works on MSS-CRC, it should work on similar cancers (non-small-cell lung cancer) with large patient populations and peak sales potential in the tens of billions/year.
- Nearer term, the IPO of AGEN's MiNK Therapeutics subsidiary may unlock more value than AGEN itself at $6/share based on recent peer IPOs.
- Agenus' vast pipeline, including multiple Big Pharma partnerships (Merck, BMY, Gilead & Incyte), its PD1 (Bal) 12/16/2021 PDUFA date, QS-21/Stimulon assets (used in Shingrix) & MiNK IPO mitigate long-term risk.
For further details see:
Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains